Appendix H. Table 5. Followup urine biochemical measures for magnesium trials

| **Study** | **Treatment Groups, Urine Collection Method**  | **Calcium,****Oxalate,****Ca-Ox Product,** **Ca-Ox Supersaturation** | **Uric Acid, Uric-A Supersaturation** | **Phosphate, Ca-P Supersaturation** | **Citrate, Sodium, Magnesium** | **Potassium (K), Volume, pH** |
| --- | --- | --- | --- | --- | --- | --- |
| Ettinger, 198812 | A. Chlorthalidone 25 mg/d (n=19)B. Chlorthalidone 50 mg/d (n=23)C. Magnesium hydroxide 650 mg/d (n=30)D. Magnesium hydroxide 1300 mg/d (n=21)E. Placebo (n=31)24 hour collectionStudy reported any data on participant compliance/adherence: Yes (medication compliance confirmed by tablet count – no results reported) | CALCIUMBaselineMean mg/24 hr(SD): A (n=19) 271 (125)B (n=23) 299 (138)C (n=30) 275 (127)D (n=21) 247 (136)E (n=31) 232 (117)% hyperCa: A (n=19) 15.8B (n=23) 13.0C (n=30) 13.3D (n=21) 14.3E (n=31) 9.7F/u Time 1: 24 mo.Mean (SD):A (n=19) 196 [p<0.01]B (n=23) 233 [p<0.01]C (n=30) no signif changeD (n=21) no signif changeE (n=31) no signif change% hyperCa: NR | URIC ACIDBaselineMean mg/24 hr(SD): A (n=19) 768 (207)B (n=23) 826 (206)C (n=30) 837 (257)D (n=21) 734 (181)E (n=31) 699 (210)% hyperUA: A (n=19) 21.1B (n=23) 26.1C (n=30) 6.7D (n=21) 9.5E (n=31) 9.7F/u Time 1: mo.Mean mg/24 hr(SD): All groups- no signif change% hyperUA: NRURIC-A SUPERSATBaselineMean (SD): NRF/u Time 1: mo.Mean (SD): NR | PHOSPHATEBaselineNMean (SD): NR% hyperP: NRF/u Time 1: mo.NMean (SD): NR% hyperP: NRCA-P SUPERSATBaselineNMean (SD): NRF/u Time 1: mo.NMean (SD): NR | CITRATEBaselineNMean (SD): NR% hypoCit: NRF/u Time 1: mo.NMean (SD): NR% hypoCit: NRSODIUMBaselineNMean (SD): NR% hyperNa: NRF/u Time 1: mo.NMean (SD): NR% hyperNa: NRMAGNESIUMBaselineMean mg/24 hr(SD): A (n=19) 93 (33)B (n=23) 97 (38)C (n=30) 91 (27)D (n=21) 97 (27)E (n=31) 95 (45)% hypoMg: NR | POTASSIUMBaselineNMean (SD): NR% hypoK: NRF/u Time 1: mo.NMean (SD): NR% hypoK: NRVOLUMEBaselineMean mL/24 hr(SD): A (n=19) 1744 (720)B (n=23) 1671 (690)C (n=30) 1894 (814)D (n=21) 1579 (675)E (n=31) 1482 (671)F/u Time 1: 24 mo.Mean mL/24 hr(SD): All groups- no signif changepHBaselineNMean (SD): NR |

Appendix H. Table 5. Followup urine biochemical measures for magnesium trials (continued)

| **Study** | **Treatment Groups, Urine Collection Method**  | **Calcium,****Oxalate,****Ca-Ox Product,** **Ca-Ox Supersaturation** | **Uric Acid, Uric-A Supersaturation** | **Phosphate, Ca-P Supersaturation** | **Citrate, Sodium, Magnesium** | **Potassium (K), Volume, pH** |
| --- | --- | --- | --- | --- | --- | --- |
|  |  | OXALATEBaselineMean mg/24 hr(SD): A (n=19) 21 (16)B (n=23) 19 (12)C (n=30) 29 (19)D (n=21) 28 (19)E (n=31) 23 (15)% hyperOx: NRF/u Time 1: 24 mo.Mean mg/24 hr(SD): A (n=19) 8 [p<0.05]B (n=23) 14 [not signif]C (n=30) no signif changeD (n=21) no signif changeE (n=31) no signif change % hyperOx: NRCA-OX PRODUCTBaselineNMean (SD): NRTime 1: mo.NMean (SD): NRCA-OX SUPERSATBaselineNMean (SD): NRTime 1: mo.NMean (SD): NR |  |  | F/u Time 1: 24 mo.Mean mg/24 hr(SD): A (n=19) no signif changeB (n=23) no signif changeC (n=30) 137 [p<0.001]D (n=21) 148 [p<0.001]E (n=31) no signif change% hypoMg: NR | pHBaselineNMean (SD): NRF/u Time 1: mo.NMean (SD): NR |

**Abbreviation:** NR = not reported